Figure 2. BCL2A1 was associated with the malignancy of gliomas. (A) TCGA, CGGA, Rembrandt and Gravendeel datasets were utilized to assess the expression of BCL2A1 in tumors of different grades. (B, C) IHC staining of BCL2A1 in LGG and GBM tissues. (D) BCL2A1 expression in gliomas with different IDH and 1p19q statuses in TCGA and CGGA datasets. (E) The expression of BCL2A1 in gliomas with different IDH and 1p19q statuses was analyzed by immunohistochemistry. Abbreviations: mut: mutation; WT: wild type; codel: codeletion; non-codel: non-codeletion. *P < 0.05, **P < 0.01. ***P < 0.001, ****P < 0.0001.